These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 29074545)

  • 1. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
    Raghu G
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
    Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
    Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 13. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 17. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 19. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.